Search

• GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19

  Media

  GSK and Vir continue discussions with global regulators to make VIR-7831 available to patients with COVID-19.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-ema-review-of-dual-action-monoclonal-antibody-vir-7831-for-the-early-treatment-of-covid-19/

  First published: 15 April 2021

• EMA issues positive scientific opinion on GSK and Vir Biotechnology’s sotrovimab for the early treatment of COVID-19

  Media

  Opinion based on the EMA’s CHMP review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19.

  https://www.gsk.com/en-gb/media/press-releases/ema-issues-positive-scientific-opinion-on-gsk-and-vir-biotechnology-s-sotrovimab-for-the-early-treatment-of-covid-19/

  First published: 21 May 2021

• 

  ‘It can get very serious, very quickly’: the symptoms, risks, and ways to prevent pneumonia everyone should know about

  Behind the science magazine

  Pneumonia is a respiratory disease spread through contact with infected droplets of saliva or mucus – and it can be deadly.

  https://www.gsk.com/en-gb/behind-the-science-magazine/pneumonia-symptoms-risks-vaccines-treatment/

  First published: 10 November 2023

• MHRA grants conditional marketing authorisation1 for COVID-19 treatment Xevudy (sotrovimab)

  Media

  Conditional marketing authorisation has been granted for Great Britain and is based on Phase III data

  https://www.gsk.com/en-gb/media/press-releases/mhra-grants-conditional-marketing-authorisation1-for-covid-19-treatment-xevudy-sotrovimab/

  First published: 02 December 2021

• Strong performance and momentum drive upgraded guidance

  Media

  Q2 2023 performance highlights

  https://www.gsk.com/en-gb/media/press-releases/strong-performance-and-momentum-drive-upgraded-guidance/

  First published: 26 July 2023

• GSK to present updates on its industry-leading infectious disease portfolio at IDWeek 2022

  Media

  GSK will share updates on its industry-leading infectious disease pipeline and portfolio with 33 abstracts accepted for IDWeek 2022.

  https://www.gsk.com/en-gb/media/press-releases/gsk-to-present-updates-on-its-industry-leading-infectious-disease-portfolio-at-idweek-2022/

  First published: 12 October 2022

• GSK presents new data at the Alzheimer's Association International Conference 2024

  Media

  ZOSTER-122 retrospective study presented during Featured Research Session on shingles and dementia risk

  https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-at-the-alzheimers-association-international-conference-2024/

  First published: 30 July 2024

• GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

  Media

  Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions/

  First published: 06 April 2020

• GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab

  Media

  GlaxoSmithKline plc and Vir Biotechnology, Inc. announce the supply of 220,000 doses of sotrovimab for adults and adolescents with COVID-19.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-joint-procurement-agreement-with-european-commission-for-covid-19-treatment-sotrovimab/

  First published: 28 July 2021

• Results announcement for the fourth quarter 2015

  Media

  GSK delivers further progress with 2015 sales of £24 billion (+6%), core EPS 75.7p (-15%) and total EPS 174.3p, +>100% CER 2016

  https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2015/

  First published: 03 February 2016